Abstract
During the process of tumorigenesis, certain cancers are known to develop deficiencies in one or more major pathways of DNA damage repair, rendering them critically dependent on alternative repair processes for maintaining genomic integrity and viability. Targeting these alternative DNA repair mechanisms is a potentially highly-specific anticancer strategy, as their inhibition is theoretically toxic only to tumor cells and not to normal tissues. We will review here the rationale behind this strategy and provide examples of its application. We will also discuss several as yet unanswered questions surrounding this strategy, including whether human cancers frequently harbor synthetically lethal interactions in DNA repair and, if so, how patients might be identified who would benefit from targeting such interactions.
Keywords: Radiation, chemotherapy, DNA repair, double-strand break repair, non-homologous end joining, homologous recombination, Tumorigenesis, Homologous recobmination, Mutation, Tumor-specific phenotype, PARP inhibitor, BRCA-defective tumors, Translocation, Genetic mutation, Amplification, Oncogenic stress, Cytotoxic drugs, Radiomimetics, NHEJ, PARP proteins, PARP inhibitors, Biomarkers, Oncology
Current Drug Targets
Title: Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Volume: 11 Issue: 10
Author(s): Benjamin J. Moeller, Wadih Arap and Renata Pasqualini
Affiliation:
Keywords: Radiation, chemotherapy, DNA repair, double-strand break repair, non-homologous end joining, homologous recombination, Tumorigenesis, Homologous recobmination, Mutation, Tumor-specific phenotype, PARP inhibitor, BRCA-defective tumors, Translocation, Genetic mutation, Amplification, Oncogenic stress, Cytotoxic drugs, Radiomimetics, NHEJ, PARP proteins, PARP inhibitors, Biomarkers, Oncology
Abstract: During the process of tumorigenesis, certain cancers are known to develop deficiencies in one or more major pathways of DNA damage repair, rendering them critically dependent on alternative repair processes for maintaining genomic integrity and viability. Targeting these alternative DNA repair mechanisms is a potentially highly-specific anticancer strategy, as their inhibition is theoretically toxic only to tumor cells and not to normal tissues. We will review here the rationale behind this strategy and provide examples of its application. We will also discuss several as yet unanswered questions surrounding this strategy, including whether human cancers frequently harbor synthetically lethal interactions in DNA repair and, if so, how patients might be identified who would benefit from targeting such interactions.
Export Options
About this article
Cite this article as:
J. Moeller Benjamin, Arap Wadih and Pasqualini Renata, Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011336
DOI https://dx.doi.org/10.2174/1389450111007011336 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Fertility Preservation for Young Women with Cancer: Hope for the Future
Current Women`s Health Reviews Molecular Targeting of ERKs/RSK2 Signaling in Cancers
Current Pharmaceutical Design Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry RNA Interference as Therapeutics for Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Does Ligand Symmetry Play a Role in the Stabilization of DNA G-Quadruplex Host-Guest Complexes?
Current Medicinal Chemistry Immunobiologic Agents in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Current Genomics From Cochlear Cell Death Pathways To New Pharmacological Therapies
Mini-Reviews in Medicinal Chemistry The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Current Topics in Medicinal Chemistry Nanotechnology and Animal Health
Pharmaceutical Nanotechnology Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Current Pharmaceutical Biotechnology The Pim Kinases: New Targets for Drug Development
Current Drug Targets Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs